AzTrials
AzTrials

Chronic InsomniaNCT04024787

Impact of Insomnia Treatment on Brain Responses During Resting-state and Cognitive Tasks

A study testing Cognitive-Behavioural therapy for insomnia (CBT-I) in people with Chronic Insomnia, run by Concordia University, Montreal at 1 site in Canada.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

Individuals with chronic insomnia have persistent difficulty falling and staying asleep, as well as complaints of altered daytime functioning that may be associated with cognitive impairments. Read more about this study

Who is it for?
Ages 25 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Chronic Insomnia
What is being tested?
Cognitive-Behavioural therapy for insomnia (CBT-I)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteCanada
Study dates
30 Jul 2019to 30 Dec 2026
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 80 participants with chronic primary insomnia (40 per group) 40 good sleepers

Who cannot join

  • Older than 65 y.o. or younger than 25 y.o.
  • Contraindication to the MRI scanning
  • Current neurological disorder
  • Past history of brain lesion
  • Major surgery (i.e., requiring general anesthesia) in the past 3 months
  • Untreated thyroid disorder
Show all 31Show fewer
  • Chronic pain syndrome self-reported as interfering with sleep
  • Recent and severe infection in the past 3 months
  • Active cancer, or remitted cancer with cancer treatment within the last 2 years
  • Stroke
  • Myocardial infarct
  • Arterial bypass or angioplasty
  • Pacemaker
  • Heart failure causing limitation of ordinary physical activity
  • Renal insufficiency
  • Sleep apnea with an apnea-hypopnea index > 5/h
  • Restless legs syndrome with symptoms 3 days or more per week
  • Periodic limb movements during sleep with index > 15/h
  • REM-sleep behavior disorder
  • Narcolepsy and other central disorders of hypersomnolence
  • Sleepwalking more than once/month
  • Having worked on night shifts or rotating shifts for more than 2 weeks in the last 3 months or expecting to do so during the study period
  • Severe mental disorders: bipolar disorder (Type I), schizophrenia, anxiety disorders, major depressive disorder, current substance use disorder, current post-traumatic stress disorder
  • Current suicidality
  • Frequent alcohol consumption (>10 glasses/week) or use of cannabis (more than once a week) or illicit drugs (more than once a month)
  • Smoking cigarettes more than 10 cigarettes/day
  • Pregnant or breastfeeding women
  • Current psychotherapy or past cognitive-behavioural therapy for insomnia
  • Current use of medication for depression or anxiety
  • Unable to stop hypnosedative medications for at least 2 weeks prior to the first assessment
  • For good sleepers: insomnia symptoms more than 3 times/ week.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Perform Center, Concordia University

    Montreal, Quebec, H4B 1R6

Other trials in Canada

About this study

Official title: Neural Responses and Connectivity During Rest, Memory Encoding and Emotional Stimulation in Chronic Insomnia, and Their Relationships With Insomnia Treatment: a Wait-list Controlled Randomized Trial of Cognitive-behavioural Therapy for Insomnia

Individuals with chronic insomnia have persistent difficulty falling and staying asleep, as well as complaints of altered daytime functioning that may be associated with cognitive impairments. The neural processes underlying these daytime complaints may involve abnormal activation of brain regions and neural networks involved in working memory, memory encoding and emotions. The goal of this study is to assess whether a psychological treatment for insomnia will reverse these abnormalities in brain responses to cognitive tasks and at rest. A secondary objective of the study is to characterize impairments in attentional processing and assess if the impairments can be reversed by the psychological treatment. We hypothesized that the psychological treatment for insomnia will lead to a normalization of the brain responses to working memory, declarative memory encoding, insomnia-related stimuli, and the functional connectivity within the default-mode and limbic networks.

Read the detailed description

Study hypothesis

Brain responses associated with working memory task and declarative memory encoding will be decreased in chronic insomnia compared to good sleepers and, among individuals with chronic insomnia, cognitive-behavioral therapy for insomnia will lead to larger recovery in these brain responses, compared to a 3-month wait period.

Brain responses to emotional stimulation, especially to insomnia-related stimuli, will be increased in chronic insomnia compared to good sleepers, and, among individuals with chronic insomnia, cognitive-behavioral therapy for insomnia will lead to larger reduction in these brain responses, compared to a 3-month wait period.

Connectivity in the default-mode and limbic networks during resting-state will be increased in chronic insomnia compared to good sleepers, and, among individuals with chronic insomnia, cognitive-behavioral therapy for insomnia will lead to larger reduction in this connectivity, compared to a 3-month wait period.

Being tested
Cognitive-Behavioural therapy for insomnia (CBT-I)
Medical subject headings
Sleep Initiation and Maintenance Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive-Behavioural therapy for insomnia (CBT-I)Behavioural

    Participants with chronic primary insomnia are randomized into 2 groups with a 1:1 allocation ratio, after the completion of the pre-treatment assessment. Post-treatment and post-waitlist assessment occur after the 3-month treatment or waiting period.

    One group will receive the intervention immediately after the pre-treatment assessment and the other group will receive the intervention after a waiting period of 3 months. The intervention consists of manualized cognitive-behavioural therapy for insomnia. This treatment includes psychoeducation about sleep and circadian rhythms, stimulus control, sleep restriction, relaxation, and cognitive therapy. The therapy is administered individually. Participants meet for 8 sessions of 50 minutes spread over 12 weeks.

Study groups in NCT04024787
Study groupRoleWhat they receive
Immediate interventionExperimentalNot described
Receives: Behavioral: Cognitive-Behavioural therapy for insomnia (CBT-I)
WaitlistNo interventionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Functional magnetic resonance imaging (fMRI) to examine brain responses to working memory with increasing task difficulty

    Functional magnetic resonance imaging (fMRI) will be used to look at changes in brain activations to working memory in individuals with chronic insomnia compared to good sleepers, as well as the modifications in these brain activations after cognitive-behavioral therapy for insomnia.

    Measured: 3 months

  2. Functional magnetic resonance imaging (fMRI) to examine brain responses to declarative memory encoding

    Functional magnetic resonance imaging (fMRI) will be used to look at changes in brain activations to declarative memory encoding in individuals with chronic insomnia compared to good sleepers, as well as the modifications in these brain activations after cognitive-behavioral therapy for insomnia.

    Measured: 3 months

  3. Functional magnetic resonance imaging (fMRI) to examine brain responses to insomnia-related stimuli

    Functional magnetic resonance imaging (fMRI) will be used to look at changes in brain activations to insomnia-related pictures in individuals with chronic insomnia compared to good sleepers, as well as the modifications in these brain activations after cognitive-behavioral therapy for insomnia.

    Measured: 3 months

  4. Functional magnetic resonance imaging (fMRI) to examine functional connectivity within the default-mode and limbic networks at rest

    Functional magnetic resonance imaging (fMRI) will be used to look at changes in resting state functional connectivity in individuals with chronic insomnia compared to good sleepers, as well as the modifications in this functional connectivity after cognitive-behavioral therapy for insomnia, with a focus on the default-mode and limbic networks.

    Measured: 3 months

Secondary outcomes (44)
  1. Insomnia Severity Index (ISI)

    Self-reported insomnia severity

    Measured: 3 months and 1 year

  2. Pittsburgh Sleep Quality Index (PSQI)

    Self-reported sleep quality

    Measured: 3 months and 1 year

  3. Total sleep time

    Self-reported total sleep time from 14-day sleep diary

    Measured: 3 months and 1 year

  4. Total sleep time

    Total sleep time from 14-day actigraphy

    Measured: 3 months

  5. Sleep latency

    Self-reported sleep latency from 14-day sleep diary

    Measured: 3 months and 1 year

  6. Sleep latency

    Sleep latency from 14-day actigraphy

    Measured: 3 months

  7. Wake-after-sleep-onset (WASO)

    Self-reported duration of wake-after-sleep-onset from 14-day sleep diary

    Measured: 3 months and 1 year

  8. Wake-after-sleep-onset (WASO)

    Duration of wake-after-sleep-onset from 14-day actigraphy

    Measured: 3 months

  9. Sleep efficiency

    Self-reported sleep efficiency from 14-day sleep diary

    Measured: 3 months and 1 year

  10. Sleep efficiency

    Sleep efficiency from 14-day actigraphy

    Measured: 3 months

  11. Diagnosis of insomnia disorder

    A trained interviewer evaluates the presence of an insomnia disorder using the SCID-V

    Measured: 3 months and 1 year

  12. PSG total sleep time

    Total sleep time from overnight polysomnography

    Measured: 3 months

  13. PSG sleep latency

    Sleep latency from overnight polysomnography

    Measured: 3 months

  14. PSG wake-after-sleep-onset (WASO)

    Duration of wake-after-sleep-onset from overnight polysomnography

    Measured: 3 months

  15. PSG sleep efficiency

    Sleep efficiency from overnight polysomnography

    Measured: 3 months

  16. Sleep stage durations (N1, N2, N3, REM)

    Durations of each sleep stage from overnight polysomnography

    Measured: 3 months

  17. Arousal index

    Number of EEG arousals per hour from overnight polysomnography

    Measured: 3 months

  18. Spindle density

    Number of sleep spindles per minute of stage N2-N3 sleep from overnight polysomnography

    Measured: 3 months

  19. Dim light melatonin onset (DLMO)

    Objective measure of central circadian timing (dim light melatonin onset; DLMO) will be obtained from hourly evening saliva samples

    Measured: 3 months

  20. Cortisol

    Cortisol will be assessed using salivary samples collected at bedtime, awakening and 45 minutes after awakening

    Measured: 3 months

  21. Heart rate variability

    Heart rate variability will be measured using the electrocardiogram leads during the overnight assessments

    Measured: 3 months

  22. Blood pressure

    Blood pressure is assessed using an oscillometer measurement of systolic and diastolic blood pressure in the morning following the overnight assessments

    Measured: 3 months

  23. Circulating interleukin-6

    Markers will be quantified using blood sample during the overnight assessments

    Measured: 3 months

  24. Circulating tumor necrosis factor-alpha

    Markers will be quantified using blood sample during the overnight assessments

    Measured: 3 months

  25. Circulating C-reactive protein

    Markers will be quantified using blood sample during the overnight assessments

    Measured: 3 months

  26. Circulating neurotrophic factor BDNF

    Markers will be quantified using blood sample during the overnight assessments

    Measured: 3 months

  27. Beck Depression Inventory (BDI)

    Measured: 3 months and 1 year

  28. State-Trait Inventory for Cognitive and Somatic Anxiety (STICSA)

    Measured: 3 months and 1 year

  29. Sahlgrenska Academy Self-reported Cognitive Impairment Questionnaire (SASCI-Q, adapted version)

    Questionnaire assessing self-reported (subjective) memory complaints. Total score ranges from 29 to 203 (higher score reflects more self-reported cognitive complaints).

    Measured: 3 months and 1 year

  30. Work and Social Adjustment Scale (WSAS)

    Self-reported measure assessing perceived functional impairment associated with insomnia. Total score ranges from 0 to 40 (lower score reflects less impairment).

    Measured: 3 months and 1 year

  31. The Implicit Positive and Negative Affect Test (IPANAT)

    Measured: 3 months and 1 year

  32. Beliefs and Attitudes about Sleep (DBAS)

    Measured: 3 months and 1 year

  33. Daytime Insomnia Symptom Response Scale (DISRS)

    Self-report measures assessing sleep-related rumination

    Measured: 3 months and 1 year

  34. Attention

    Attention will be assessed using computerized divided attention and multitasking tasks assessed in the evening and morning of the overnight assessments

    Measured: 3 months

  35. Gray matter volume (GMV)

    Brain morphometric measure from MRI

    Measured: 3 months

  36. Cortical thickness

    Brain morphometric measure from MRI

    Measured: 3 months

  37. White matter integrity (fractional anisotropy, mean diffusivity)

    Brain measure from MRI

    Measured: 3 months

  38. GABA

    GABA concentration from Magnetic Resonance Spectroscopy (in the anterior cingulate cortex)

    Measured: 3 months

  39. Trier Inventory for Chronic Stress - short form

    Measured: 3 months and 1 year

  40. Subjective happiness scale

    Self-reported measure of global subjective happiness. Total score ranges from 4 to 28 (higher score reflects greater happiness).

    Measured: 3 months and 1 year

  41. Temporal experience of pleasure scale (adapted version)

    Self-reported measure of anticipatory and consummatory facets of pleasure. Total score ranges from 18 to 52 (higher score reflects greater pleasure).

    Measured: 3 months and 1 year

  42. Fatigue symptom inventory

    Measured: 3 months and 1 year

  43. Positive and Negative Affect Schedule

    Measured: 3 months and 1 year

  44. Munich Chronotype Questionnaire (MCTQ)

    Questionnaire on self-reported sleep habits, assessing individual chronotype (e.g., early type, normal type late type).

    Measured: 3 months and 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jul 2019
  2. Study start30 Jul 2019
  3. Primary completion30 May 2026
  4. Study completion30 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This study is a randomized controlled trial. Participants with chronic insomnia are randomized to either immediate cognitive-behavioural therapy or a 3-month wait-list period using a 1:1 allocation ratio. Randomization is conducted with block sizes of 4 participants. Randomization results are contained in sealed opaque envelopes that are opened in the presence of the participants after the completion of the pre-treatment assessment. A second assessment will be conducted after the treatment or waiting period. A follow-up assessment is conducted 12 months after the completion of the post-treatment assessment. A group of good sleepers, matched on age and gender with the insomniacs, will also be recruited and assessed at baseline only to provide a normative reference group.
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04024787
Sponsor's protocol ID
30011416
Status last verified
Mar 2026
First submitted
12 Jul 2019
Last updated
22 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in